SOURCES AND USES OF FUNDS
HSV2 Funding Sources (2002-2019)
Equity/profits from a preclinical CRO $ 4.0 million
US Public Health Service $ 3.0 million
SBIR grants from NIH-NIAID for HSV2 $ 6.9 million
SBIR grant from NIH-NIAID for RSV $ 0.6 million
Total $14.5 million
HSV2 Program Anticipated Expenditures
Technical consulting services $ 0.80 million
Patents and licenses $ 0.15 million
Legal, rent, insurance $ 0.05 million
Stability testing and formulations $ 0.30 million
Contingencies $ 0.25 million
Total $ 1.55 million
In services support via NIAID
Liposomes $ 0.42 million
